We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

TCL:ASXTransurban Group Ltd. Analysis

Data as of 2026-06-12 - not real-time

A$15.61

Latest Price

4/10Risk

Risk Level: Medium

Executive Summary

Transurban Group trades at an eye‑watering PE of 104, far above the industry average of ~30, suggesting the stock is heavily overvalued despite a solid 8.2% revenue growth and a generous 4.36% dividend yield. However, the dividend payout ratio exceeds 400%, the balance sheet is strained with a debt‑to‑equity of 228, and free cash flow is modest relative to debt, raising serious questions about the sustainability of the current income stream. On the technical side, the stock sits just below the 52‑week high of 15.62, faces a strong resistance near 15.62 and support around 14.19, while an RSI of 75 signals overbought conditions; the MACD remains bullish but the upside is limited. The low beta (~0.05) and increasing volume point to limited market‑wide volatility, yet the high volatility of ~15.8% over 30 days and the extreme greed sentiment (fear‑greed index 88.9) hint at potential short‑term pull‑backs. Overall, the combination of inflated valuation, unsustainable dividend policy, and heavy leverage outweighs the attractive yield, making the stock a risky bet for income‑focused investors.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 5/10

Key Factors

  • RSI at 75 indicates overbought conditions
  • Price is near resistance with limited upside
  • Bullish MACD but high PE limits short‑term gains

Medium Term

1–3 years
Neutral
Model confidence: 6/10

Key Factors

  • Attractive dividend yield but unsustainable payout ratio
  • Strong cash flow generation offset by very high debt load
  • Revenue growth remains healthy at ~8%

Long Term

> 3 years
Cautious
Model confidence: 7/10

Key Factors

  • Extreme overvaluation relative to earnings and peers
  • Debt‑to‑equity of 228 threatens financial stability
  • Dividend may be cut if cash generation cannot support current payouts

Key Metrics & Analysis

Financial Health

Revenue Growth8.20%
Profit Margin12.19%
P/E Ratio104.1
ROE5.36%
ROA2.08%
Debt/Equity228.43
P/B Ratio5.5
Op. Cash FlowA$1.6B
Free Cash FlowA$570.6M
Industry P/E30.6

Technical Analysis

TrendNeutral
RSI75.2
SupportA$14.19
ResistanceA$15.62
MA 20A$14.82
MA 50A$14.31
MA 200A$14.32
MACDBullish
VolumeIncreasing
Fear & Greed Index88.89

Valuation

Target PriceA$13.99
Upside/Downside-10.40%
GradeOvervalued
TypeValue
Dividend Yield4.36%

Risk Assessment

Beta0.05
Volatility15.77%
Sector RiskLow
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.